- Open
- 1655.63
- High
- 1666.80
- Low
- 1592.00
- Close
- 1592.00
- Change
- -44.00 (-2.69%)
- Volume
- 16,771
| 18 Sept 2026 | 17:12:00 | Transaction in Own Shares |
| 18 Sept 2026 | 13:21:00 | Net Asset Value(s) |
| 17 Sept 2026 | 14:20:00 | Net Asset Value(s) |
| 16 Sept 2026 | 15:37:00 | Net Asset Value(s) |
| 15 Sept 2026 | 14:35:00 |
| 4 Jun 2026 | Annual Report for the Year Ended 31 March 2026 | |
| 3 Jun 2026 | Annual Report for the year ended 31 March 2026 | |
| 5 Jun 2025 | The Biotech Growth Trust PLC-Annual Report for the year ended 31 March 2025 |
The Biotech Growth Trust PLC invests in a diversified portfolio of global biotechnology companies, focusing on long-term capital appreciation. Its investment objective is to provide exposure to the biotechnology sector, targeting growth opportunities within this industry. The trust is managed by Frostrow Capital LLP as the Alternative Investment Fund Manager and OrbiMed Capital LLC as the Portfolio Manager, adhering to specific investment guidelines. It operates within the Biotechnology & Healthcare sector, making it a peer of other trusts with similar mandates and asset classes.
| 18 Sept 2026 | 17:12:00 | Transaction in Own Shares |
| 18 Sept 2026 | 13:21:00 | Net Asset Value(s) |
| 17 Sept 2026 | 14:20:00 | Net Asset Value(s) |
| 16 Sept 2026 | 15:37:00 | Net Asset Value(s) |
| 15 Sept 2026 | 14:35:00 |
| 4 Jun 2026 | Annual Report for the Year Ended 31 March 2026 | |
| 3 Jun 2026 | Annual Report for the year ended 31 March 2026 | |
| 5 Jun 2025 | The Biotech Growth Trust PLC-Annual Report for the year ended 31 March 2025 |
The Biotech Growth Trust PLC invests in a diversified portfolio of global biotechnology companies, focusing on long-term capital appreciation. Its investment objective is to provide exposure to the biotechnology sector, targeting growth opportunities within this industry. The trust is managed by Frostrow Capital LLP as the Alternative Investment Fund Manager and OrbiMed Capital LLC as the Portfolio Manager, adhering to specific investment guidelines. It operates within the Biotechnology & Healthcare sector, making it a peer of other trusts with similar mandates and asset classes.
| Net Asset Value(s) |
| 28 Jul 2026 |
| Biotech Growth makes 14-times return on Forte Biosciences accepting $2.2bn bid from Argenx SE |
| Net Asset Value(s) |
| 28 Jul 2026 |
| Biotech Growth makes 14-times return on Forte Biosciences accepting $2.2bn bid from Argenx SE |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £765m | +0.1% | |
| £751m | +0.2% | |
| £513m | +0.1% | |
BIOGThe Biotech Growth Trust PLC | £302m | +0.7% |
| £240m | -0.1% | |
| £227m | +0.1% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £765m | +0.1% | |
| £751m | +0.2% | |
| £513m | +0.1% | |
BIOGThe Biotech Growth Trust PLC | £302m | +0.7% |
| £240m | -0.1% | |
| £227m | +0.1% |
